Doctors gave a fecal transplant (a poop pill or enema) to 12 cancer patients whose immune therapy wasn't working. The donor poop came from patients who did respond to the therapy. A week later, they found the donor bacteria in 8 out of 10 patients, but it didn't stay for long in most of them. Only one patient kept the donor bacteria long-term, and that patient also got better.
See the scientific wording
In a trial of 12 patients with advanced ICI-refractory cancers receiving fecal microbiota transplantation (FMT) from donors who had responded to ICIs, donor microbiota engraftment was detected in 8 of 10 evaluable patients one week after the first FMT, but engraftment was often transient; the only patient with durable engraftment also achieved clinical benefit.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman2026
The study gave fecal transplants to cancer patients and found that most patients had some donor bacteria at first, but it didn't last. The one patient who kept the bacteria also did well, which matches the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
During a fecal transplant, donor bacteria are placed into the gut. These bacteria usually leave quickly, but sometimes they stay. If they stay, they change the immune system to attack cancer more effectively. This helps the patient get better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Doctors gave a fecal transplant (a poop pill or enema) to 12 cancer patients whose immune therapy wasn't working. The donor poop came from patients who did respond to the therapy. A week later, they found the donor bacteria in 8 out of 10 patients, but it didn't stay for long in most of them. Only one patient kept the donor bacteria long-term, and that patient also got better.
Mechanism
1 studyDonor bacteria can change the immune system to fight cancer if they stay in the gut. In the one patient where they stayed, the cancer stopped growing. This change in the immune system helps the body control cancer.
During a fecal transplant, donor bacteria are placed into the gut. These bacteria usually leave quickly, but sometimes they stay. If they stay, they change the immune system to attack cancer more effectively. This helps the patient get better.
Fecal microbiota transplantation introduces donor gut microbes into the recipient's intestines.
The donor microbes temporarily colonize the recipient's gut, altering the local microbial community.
In most patients, this colonization is transient and the donor microbes disappear within weeks.
In a minority of patients, the donor microbes establish durable engraftment, maintaining a modified microbiome over time.
Durable engraftment leads to sustained stimulation of the immune system, shifting it toward an anti-tumor state.
This anti-tumor immune state restores sensitivity to immune checkpoint inhibitors, resulting in clinical benefit such as stable disease or prolonged survival.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study gave fecal transplants to cancer patients and found that most patients had some donor bacteria at first, but it didn't last. The one patient who kept the bacteria also did well, which matches the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Fecal Microbiota Transplantation in Cancer Patients Treated with Immune Checkpoint Inhibitors
Population: patients with ICI-refractory cancers; Intervention: FMT from responders; Comparator: placebo or no FMT; Outcome: overall response rate, progression-free survival, engraftment durability; Duration: at least 12 months follow-up.
Double-Blind, Randomized, Placebo-Controlled Trial of FMT from Responder Donors vs Placebo for ICI-Refractory Cancers
Population: patients with advanced ICI-refractory cancers; Intervention: FMT from donors who responded to ICIs; Comparator: placebo (sham transplant); Outcome: rate of durable engraftment, objective response rate, survival; Duration: at least 6 months.
Prospective Cohort Study of FMT in ICI-Refractory Patients: Predicting Durable Engraftment and Clinical Outcomes
Population: patients receiving FMT for ICI-refractory cancers; exposure: donor microbiota composition; outcome: durable engraftment and response; follow-up for clinical outcomes; collect baseline and serial microbiome samples.
Case-Control Study of Engraftment and Clinical Benefit in ICI-Refractory Patients Receiving FMT
Cases: patients with durable engraftment and clinical benefit; Controls: patients with transient or no engraftment; Retrospective chart review and microbiome analysis of stored samples; compare microbial signatures and clinical characteristics.